Modulation of endothelial cell inflammatory integrins and stress markers with rh-factor VIIa in patients with advanced chronic hepatitis C

Journal of Viral Hepatitis

Volumn 10, Issue 4, 2003, Pages 310-317

  Van Thiel, D H ^a   Anantharaju, A ^a   Mindikoglu, A L ^a   Shah, N ^a   Leone, N ^a   Bejna, J ^a   Tarasuk, G ^a   Todo, A ^a   Mobarhan, S ^a   George, M ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Coagulation; Fibrinolysis; Hepatitis C; Integrins; Stress markers

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LIPOCORTIN 5; NITROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UREA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HEPATITIS C; HUMAN; INFLAMMATION; LIVER CIRRHOSIS; MALE; MODULATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; TIME SERIES ANALYSIS; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ANNEXIN A5; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; INTEGRINS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STRESS; THROMBOMODULIN; THROMBOPLASTIN;

EID: 0037707396     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00429.x     Document Type: Article

References (25)

1. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis 2000; 11 Suppl 1: S69-S74.
2. Kaul VV, Munoz SJ. Coagulopathy of liver disease. Current Treatment Options in Gastroentrology 2000; 3: 433-438.
3. Francis RB Jr, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14: 460-465.
4. Hedner U. Recombinant activated factor VII or a mineral haemostatic agent. Blood Coag Fibrin 1998; 9(Suppl): S147-S152.
5. Nemerson Y. Tissue factor and hemostasis. Blood 1998; 71: 1-8.
6. Esmon NL. Thrombomodulin. Seminar Thromb Hemost 1987; 13: 454-463.
7. Hoffman R, Mahajana A, Agmon P, Baruch Y, Brenner B. Successful are of recombinant activated factor VII (NovoSeven) in controlling severe intra-abdominal bleeding after liver needle biopsy. Thromb Haemost 2002; 87: 346-347 (letter).
8. Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (Suppl 1): 159-164.
9. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 971-982.
10. Meijer K, Sieders E, Slooff MJ, de Wolf JT, van der Meer J. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII. Thromb Haemost 1998; 80: 204-205.
11. Negrier C. An update on NovoSeven: new approaches in clinical experience. European Journal of Haematology 1998; 61: 5-6.
12. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier Syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
13. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4: 574-576.
14. Ancliff P, Liesner R, Khair K, Hann I. The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath. Blood Coagulation and Fibrinolysis 1999; 10: 447-448.
15. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann Thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Throm Haemost 1999; 82: 1778.
16. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann Thrombasthenia. Blood 1999; 94: 3951-3953.
17. d'Oiron R, Menart C, Trzeciak MC et al. Use of recombinant factor VIIa in 3 patients with inherited Type 1 Glanzmann's thromboasthenia undergoing invasive procedures. Thrombosis and Hemostasis 2000; 83: 644-647.
18. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagulation and Fibrinolysis 1998; 9: 741-748.
19. Boggio L, Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. British Journal of Haematology 2001; 112: 1074-1075.
20. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplanation. Bone Marrow Transplantation 2001; 28: 405-407.
21. Vlot AJ, Ton E, Mackaay AJ, Kramer MH, Gaillard CA. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. The American Journal of Medicine 2000; 108: 421-422.
22. Moscardo F, Perez F, de la Rubia J et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. British Journal of Haematology 2001; 113: 174-176.
23. Hendriks HC, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287-289.
24. Martinowitz U, Kenet G, Segal E et al. Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma. J Trauma 2001; 51: 431-439.
25. O'Neill PA, Bluth M, Gloster ES et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52: 400-405.